bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S5 from Assessing Management of Abnormal Cervical Cancer Screening Results and Concordance with Guideline Recommendations in Three US Healthcare Settings
Authors: Cheng David , Rieu-Werden Meghan L. , Lykken Jacquelyn M. , Werner Claudia L. , Feldman Sarah , Silver Michelle I. , Atlas Steven J. , Tiro Jasmin A. , Haas Jennifer S. , Kamineni Aruna
Published: July 2024

Supplementary Table S5 shows associations between patient characteristics and guideline-concordant follow-up after the index abnormality and the initial colposcopy based on multivariable logistic regression among patients at KPWA.
Supplementary Table S4 from Assessing Management of Abnormal Cervical Cancer Screening Results and Concordance with Guideline Recommendations in Three US Healthcare Settings
Authors: Cheng David , Rieu-Werden Meghan L. , Lykken Jacquelyn M. , Werner Claudia L. , Feldman Sarah , Silver Michelle I. , Atlas Steven J. , Tiro Jasmin A. , Haas Jennifer S. , Kamineni Aruna
Published: July 2024

Supplementary Table S4 shows associations between patient characteristics and guideline-concordant follow-up after the index abnormality and the initial colposcopy based on multivariable logistic regression among patients at PH.
Supplementary Table S1 from Assessing Management of Abnormal Cervical Cancer Screening Results and Concordance with Guideline Recommendations in Three US Healthcare Settings
Authors: Cheng David , Rieu-Werden Meghan L. , Lykken Jacquelyn M. , Werner Claudia L. , Feldman Sarah , Silver Michelle I. , Atlas Steven J. , Tiro Jasmin A. , Haas Jennifer S. , Kamineni Aruna
Published: July 2024

Supplementary Table S1 shows the inclusion/exclusion criteria applied to determine the study sample and the sample size after applying each criteria to the overall and site-specific samples.
Supplementary Table S3 from Appendectomy and Risk of Prostate Cancer in the Health Professionals Follow-up Study
Authors: Zhang Yiwen , Feng Xiaotong , Giovannucci Edward L.
Published: July 2024

Supplementary Table S3 shows the history of appendectomy and risk of prostate cancer by age subgroup in the Health Professionals Follow-up Study among men with baseline age<55 years, 1986-2016.
Supplementary Table S1 from Appendectomy and Risk of Prostate Cancer in the Health Professionals Follow-up Study
Authors: Zhang Yiwen , Feng Xiaotong , Giovannucci Edward L.
Published: July 2024

Supplementary Table S1. shows the age-standardized characteristics of 49,105 participants in the Health Professionals Follow-up Study by history of appendectomy in 1986.
Supplementary Figure S2 from Serum Lipid Levels, Genetic Risk, and Lung Cancer Incidence: A Large Prospective Cohort Study
Authors: Wang Jing , Wang Qi , Shi Ziwei , Yan Xiaolong , Lei Zhiqun , Zhu Wenmin
Published: July 2024

Supplementary Figure S2 shows lung cancer incidence risk based on serum lipids with genetic categories.
Supplementary Table ST2 from Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study
Authors: Gottschlich Anna , Hong Quan , Gondara Lovedeep , Alam Md S. , Cook Darrel A. , Martin Ruth E. , Lee Marette , Melnikow Joy , Peacock Stuart , Proctor Lily , Stuart Gavin , Franco Eduardo L. , Krajden Mel , Smith Laurie W. , Ogilvie Gina S.
Published: July 2024

Supplementary Table S2. Age-adjusted hazard ratio (HR) of CIN2+ and CIN3+ detection in HPV cohorts relative to cytology-based screen cohorts
Data from Does Neighborhood Socioeconomic Status Alter Memory Change Associated with a Cancer Diagnosis? Preliminary Evidence from the US Health and Retirement Study
Authors: Westrick Ashly C. , Ospina-Romero Monica , Clarke Philippa , Langa Kenneth M. , Kobayashi Lindsay C.
Published: July 2024

AbstractBackground:
Neighborhood disadvantage has been linked to cognitive impairment, but little is known about the effect of neighborhood disadvantage on long-term cancer-related memory decline.
Methods:
Incident cancer diagnosis and memory (immediate and delayed recall, combined with proxy-reported memory) were assessed at biennial interviews in the US Health and Retirement Study (N = 13,293, 1998–2016). Neighborhood disadvantage was measured using the National Neighborhood Data Archive disadvantage index, categorized into tertiles (T1: least disadvantaged–T3: most disadvantaged). Linear mixed-effects models estimated the standardized memory trajectories in participants with or without cancer, by neighborhood disadvantage.
Results:
Living in more disadvantaged neighborhoods was associated with worse mean memory function and steeper memory declines, regardless of cancer status. An incident cancer diagnosis was associated with an acute memory drop for those living in least disadvantaged neighborhoods but not more disadvantaged neighborhoods [T1: −0.05, 95% confidence interval (CI): −0.08, −0.01; T3: −0.13, 95% CI: −0.06, 0.03]. Cancer survivors in the least disadvantaged neighborhoods had a slight memory advantage in the years prior to diagnosis (T1: 0.09, 95% CI: 0.04, 0.13) and after diagnosis (T1: 0.07, 95% CI: 0.01, 0.13).
Conclusions:
An incident cancer diagnosis among those living in the least disadvantaged neighborhoods was associated with an acute memory drop at the time of diagnosis and a long-term memory advantage before and after diagnosis compared with cancer-free individuals in similar neighborhoods.
Impact:
These findings could inform interventions to promote cancer survivor’s long-term aging. Future studies should investigate the social and biological pathways through which neighborhood socioeconomic status could influence cancer-related memory changes.
Data from Optimization and Local Cost-Effectiveness of Nasopharyngeal Carcinoma Screening Strategies in Southern China: Secondary Analysis of the Guangdong Randomized Trial
Authors: Miller Jacob A. , Liu Zhiwei , Pinsky Benjamin A. , Le Quynh-Thu , Li Tong , Yu Kelly J. , Hildesheim Allan , Cao Su-Mei
Published: July 2024

AbstractBackground:
Screening with anti-Epstein–Barr virus (EBV) serology and endoscopy decreased nasopharyngeal carcinoma (NPC) mortality in Guangdong in a randomized trial. We conducted a secondary analysis of this trial using local incidence and cost data to optimize screening programs, hypothesizing that screening could be cost-effective in southern China.
Methods:
Screening costs and life-years after NPC diagnosis were obtained from the Guangdong trial’s intent-to-screen population (men and women aged 30–69). Seropositive subjects were rescreened annually for 5 years. Thereafter, we evaluated 12 screening strategies in Guangdong and Guangxi using a validated model. Strategies used combinations of serology, nasopharyngeal swab PCR (NP PCR), endoscopy, and MRI from trial subcohorts. Incidence data and costs were obtained from local cancer registries and the provincial healthcare system.
Results:
In the intent-to-screen population, screening with serology and endoscopy was cost-effective (¥42,366/life-year, 0.52 GDP per capita). Screening for 5 to 15 years between ages 35 and 59 years met a willingness-to-pay threshold of 1.5 GDP/quality-adjusted life-years in all modeled populations. Despite doubling costs, adding MRI could be cost-effective via improved sensitivity. NP PCR triage reduced endoscopy/MRI referrals by 37%. One-lifetime screen could reduce NPC mortality by approximately 20%.
Conclusions:
EBV–based serologic screening for NPC is likely to be cost-effective in southern China. Among seropositive subjects, the preferred strategies use endoscopy alone or selective endoscopy triaged by MRI with or without NP PCR. These data may aid the design of screening programs in this region.
Impact:
These findings support population-based screening in southern China by defining the target population, cost-effectiveness, and optimized screening approach.
Data from Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study
Authors: Gottschlich Anna , Hong Quan , Gondara Lovedeep , Alam Md S. , Cook Darrel A. , Martin Ruth E. , Lee Marette , Melnikow Joy , Peacock Stuart , Proctor Lily , Stuart Gavin , Franco Eduardo L. , Krajden Mel , Smith Laurie W. , Ogilvie Gina S.
Published: July 2024

AbstractBackground:
The growing use of primary human papillomavirus (HPV) cervical cancer screening requires determining appropriate screening intervals to avoid overtreatment of transient disease. This study examined the long-term risk of cervical precancer after HPV screening to inform screening interval recommendations.
Methods:
This longitudinal cohort study (British Columbia, Canada, 2008 to 2022) recruited women and individuals with a cervix who received 1 to 2 negative HPV screens (HPV1 cohort, N = 5,546; HPV2 cohort, N = 6,624) during a randomized trial and women and individuals with a cervix with 1 to 2 normal cytology results (BCS1 cohort, N = 782,297; BCS2 cohort, N = 673,778) extracted from the provincial screening registry. All participants were followed through the registry for 14 years. Long-term risk of cervical precancer or worse [cervical intraepithelial neoplasia grade 2 or worse (CIN2+)] was compared between HPV and cytology cohorts.
Results:
Cumulative risks of CIN2+ were 3.2/1,000 [95% confidence interval (CI), 1.6–4.7] in HPV1 and 2.7/1,000 (95% CI, 1.2–4.2) in HPV2 after 8 years. This was comparable with the risk in the cytology cohorts after 3 years [BCS1: 3.3/1,000 (95% CI, 3.1–3.4); BCS2: 2.5/1,000 (95% CI, 2.4–2.6)]. The cumulative risk of CIN2+ after 10 years was low in the HPV cohorts [HPV1: 4.7/1,000 (95% CI, 2.6–6.7); HPV2: 3.9 (95% CI, 1.1–6.6)].
Conclusions:
Risk of CIN2+ 8 years after a negative screen in the HPV cohorts was comparable with risk after 3 years in the cytology cohorts (the benchmark for acceptable risk).
Impact:
These findings suggest that primary HPV screening intervals could be extended beyond the current 5-year recommendation, potentially reducing barriers to screening.
Supplementary Table S1 from Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
Authors: Cote Gregory M. , Haddox Candace L. , Choy Edwin , Merriam Priscilla A. , Mazzola Emanuele , Venkataraman Vinayak , Alcindor Thierry , Wagner Andrew J. , Demetri George D. , George Suzanne
Published: July 2024

demographics / representativeness of study participants
Supplementary Table 2 from Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features
Authors: Yang Soo-Ryum , Jayakumaran Gowtham , Benhamida Jamal , Febres-Aldana Christopher A. , Fanaroff Rachel , Chang Jason , Gedvilaite Erika , Villafania Liliana B. , Sauter Jennifer L. , Offin Michael , Zauderer Marjorie G. , Ladanyi Marc
Published: July 2024

Supplementary Table 2
Supplementary Figures 1 and 2 from Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features
Authors: Yang Soo-Ryum , Jayakumaran Gowtham , Benhamida Jamal , Febres-Aldana Christopher A. , Fanaroff Rachel , Chang Jason , Gedvilaite Erika , Villafania Liliana B. , Sauter Jennifer L. , Offin Michael , Zauderer Marjorie G. , Ladanyi Marc
Published: July 2024

Supplementary Figures 1 and 2
Supplementary Table 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors
Authors: Kim Hyung-Don , Ryu Min-Hee , Park Young Soo , Yoo Changhoon , Kim Sung-Joo , Kang Yoon-Koo
Published: July 2024

Representativeness of study participants
Supplementary Table S2 from Fraction Dose Escalation of Hypofractionated Radiotherapy with Concurrent Chemotherapy and Subsequent Consolidation Immunotherapy in Locally Advanced Non–Small Cell Lung Cancer: A Phase I Study
Authors: Zhou Rui , Liu FangJie , Zhang HongMei , Wang DaQuan , Zhang PengXin , Zheng ShiYang , Liu YiMei , Chen Li , Guo JinYu , Zou YingYi , Rong Yu-Ming , Liu Hui , Qiu Bo
Published: July 2024

Supplementary Table 2. Representativeness of Study Participants.
Supplementary Figure S1 from Fraction Dose Escalation of Hypofractionated Radiotherapy with Concurrent Chemotherapy and Subsequent Consolidation Immunotherapy in Locally Advanced Non–Small Cell Lung Cancer: A Phase I Study
Authors: Zhou Rui , Liu FangJie , Zhang HongMei , Wang DaQuan , Zhang PengXin , Zheng ShiYang , Liu YiMei , Chen Li , Guo JinYu , Zou YingYi , Rong Yu-Ming , Liu Hui , Qiu Bo
Published: July 2024

Supplementary Figure S1. The dosimetric data of proximal bronchial tree.
Supplementary Table S5 from Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
Authors: Lacouture Mario E. , Goleva Elena , Shah Neil , Rotemberg Veronica , Kraehenbuehl Lukas , Ketosugbo Kwami F. , Merghoub Taha , Maier Tara , Bang Alexander , Gu Stephanie , Salvador Trina , Moy Andrea P. , Lyubchenko Taras , Xiao Olivia , Hall Clifton F. , Berdyshev Evgeny , Crooks James , Weight Ryan , Kern Jeffrey A. , Leung Donald Y.M.
Published: July 2024

Supplementary Table S5. Checkpoint inhibitor (CPI) classes and therapeutic combinations received by study participants.
Supplementary Figure S7 from Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
Authors: Lacouture Mario E. , Goleva Elena , Shah Neil , Rotemberg Veronica , Kraehenbuehl Lukas , Ketosugbo Kwami F. , Merghoub Taha , Maier Tara , Bang Alexander , Gu Stephanie , Salvador Trina , Moy Andrea P. , Lyubchenko Taras , Xiao Olivia , Hall Clifton F. , Berdyshev Evgeny , Crooks James , Weight Ryan , Kern Jeffrey A. , Leung Donald Y.M.
Published: July 2024

Supplementary Figure S7. Graphic representation of inflammatory pathways activated by checkpoint inhibitor (CPI) therapy in selected immune-related cutaneous adverse events (ircAEs) and associated targets for cytokine-directed therapies.
Supplementary Figure S6 from Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
Authors: Lacouture Mario E. , Goleva Elena , Shah Neil , Rotemberg Veronica , Kraehenbuehl Lukas , Ketosugbo Kwami F. , Merghoub Taha , Maier Tara , Bang Alexander , Gu Stephanie , Salvador Trina , Moy Andrea P. , Lyubchenko Taras , Xiao Olivia , Hall Clifton F. , Berdyshev Evgeny , Crooks James , Weight Ryan , Kern Jeffrey A. , Leung Donald Y.M.
Published: July 2024

Supplementary Figure S6. Representative clinical images and accompanying pie charts of the response of eczema to dupilumab, pruritus to omalizumab, maculopapular rash (MPR) to systemic steroids, MPR/pruritus to benralizumab, and psoriasis to ustekinumab.
Supplementary Figure S1 from Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
Authors: Lacouture Mario E. , Goleva Elena , Shah Neil , Rotemberg Veronica , Kraehenbuehl Lukas , Ketosugbo Kwami F. , Merghoub Taha , Maier Tara , Bang Alexander , Gu Stephanie , Salvador Trina , Moy Andrea P. , Lyubchenko Taras , Xiao Olivia , Hall Clifton F. , Berdyshev Evgeny , Crooks James , Weight Ryan , Kern Jeffrey A. , Leung Donald Y.M.
Published: July 2024

Supplementary Figure S1. Flow summary of the standardized patient evaluation and specimen characterization in the study.
Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Authors: Stearns Vered , Jegede Opeyemi A. , Chang Victor T.-S. , Skaar Todd C. , Berenberg Jeffrey L. , Nand Ranveer , Shafqat Atif , Jacobs Nisha L. , Luginbuhl William , Gilman Paul , Benson Al B. , Goodman Judie R. , Buchschacher Gary L. , Henry N. Lynn , Loprinzi Charles L. , Flynn Patrick J. , Mitchell Edith P. , Fisch Michael J. , Sparano Joseph A. , Wagner Lynne I.
Published: July 2024

Supplementary Table S3: Off Treatment Reason.
Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Authors: Stearns Vered , Jegede Opeyemi A. , Chang Victor T.-S. , Skaar Todd C. , Berenberg Jeffrey L. , Nand Ranveer , Shafqat Atif , Jacobs Nisha L. , Luginbuhl William , Gilman Paul , Benson Al B. , Goodman Judie R. , Buchschacher Gary L. , Henry N. Lynn , Loprinzi Charles L. , Flynn Patrick J. , Mitchell Edith P. , Fisch Michael J. , Sparano Joseph A. , Wagner Lynne I.
Published: July 2024

Supplementary Table S1: Representativeness of Study Participants
Supplementary Figure S9 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Authors: Aparicio Ana M. , Tidwell Rebecca S.S. , Yadav Shalini S. , Chen Jiun-Sheng , Zhang Miao , Liu Jingjing , Guo Shuai , Pilié Patrick G. , Yu Yao , Song Xingzhi , Vundavilli Haswanth , Jindal Sonali , Zhu Keyi , Viscuse Paul V. , Lebenthal Justin M. , Hahn Andrew W. , Soundararajan Rama , Corn Paul G. , Zurita-Saavedra Amado , Subudhi Sumit K. , Zhang Jianhua , Wang Wenyi , Huff Chad , Troncoso Patricia , Allison James P. , Sharma Padmanee , Logothetis Christopher J.
Published: July 2024

Supplementary Figure S9. Whole exome sequencing (WES)-based identification of pathogenic somatic mutations.
Supplementary Figure S7 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Authors: Aparicio Ana M. , Tidwell Rebecca S.S. , Yadav Shalini S. , Chen Jiun-Sheng , Zhang Miao , Liu Jingjing , Guo Shuai , Pilié Patrick G. , Yu Yao , Song Xingzhi , Vundavilli Haswanth , Jindal Sonali , Zhu Keyi , Viscuse Paul V. , Lebenthal Justin M. , Hahn Andrew W. , Soundararajan Rama , Corn Paul G. , Zurita-Saavedra Amado , Subudhi Sumit K. , Zhang Jianhua , Wang Wenyi , Huff Chad , Troncoso Patricia , Allison James P. , Sharma Padmanee , Logothetis Christopher J.
Published: July 2024

Supplementary Figure S7. Major immune cell types derived from bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (S) and Unsatisfactory (US) groups.
Supplementary Figure S6 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Authors: Aparicio Ana M. , Tidwell Rebecca S.S. , Yadav Shalini S. , Chen Jiun-Sheng , Zhang Miao , Liu Jingjing , Guo Shuai , Pilié Patrick G. , Yu Yao , Song Xingzhi , Vundavilli Haswanth , Jindal Sonali , Zhu Keyi , Viscuse Paul V. , Lebenthal Justin M. , Hahn Andrew W. , Soundararajan Rama , Corn Paul G. , Zurita-Saavedra Amado , Subudhi Sumit K. , Zhang Jianhua , Wang Wenyi , Huff Chad , Troncoso Patricia , Allison James P. , Sharma Padmanee , Logothetis Christopher J.
Published: July 2024

Supplementary Figure S6. Pathway enrichment analysis.
Supplementary Figure S2 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Authors: Aparicio Ana M. , Tidwell Rebecca S.S. , Yadav Shalini S. , Chen Jiun-Sheng , Zhang Miao , Liu Jingjing , Guo Shuai , Pilié Patrick G. , Yu Yao , Song Xingzhi , Vundavilli Haswanth , Jindal Sonali , Zhu Keyi , Viscuse Paul V. , Lebenthal Justin M. , Hahn Andrew W. , Soundararajan Rama , Corn Paul G. , Zurita-Saavedra Amado , Subudhi Sumit K. , Zhang Jianhua , Wang Wenyi , Huff Chad , Troncoso Patricia , Allison James P. , Sharma Padmanee , Logothetis Christopher J.
Published: July 2024

Supplementary Figure S2. Failure-free survival in Modules 2 and 3.
Supplementary Table S2 from Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients
Authors: Nief Corrine A. , Hammer Phoebe M. , Wang Aihui , Charu Vivek , Tanweer Amina , Litkouhi Babak , Kidd Elizabeth , Gentles Andrew J. , Howitt Brooke E.
Published: July 2024

Supplemental Table 2: Clinical and Pathologic Variables of Cases and EERI False Negatives in both the Stanford-EEC cases and TCGA-UCEC recurrent patients
Supplementary Figure S1 from Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients
Authors: Nief Corrine A. , Hammer Phoebe M. , Wang Aihui , Charu Vivek , Tanweer Amina , Litkouhi Babak , Kidd Elizabeth , Gentles Andrew J. , Howitt Brooke E.
Published: July 2024

Supplemental Figure 1: Kaplan Meier Survival Curves by TCGA Molecular Subtype
Supplementary Table S6 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Authors: Han Ji W. , Lee Soon K. , Kwon Jung H. , Nam Soon W. , Yang Hyun , Bae Si H. , Kim Ji H. , Nam Heechul , Kim Chang W. , Lee Hae L. , Kim Hee Y. , Lee Sung W. , Lee Ahlim , Chang U I. , Song Do S. , Kim Seok-Hwan , Song Myeong J. , Sung Pil S. , Choi Jong Y. , Yoon Seung K. , Jang Jeong W.
Published: July 2024

Cox regression analysis predicts the OS of the derivation cohort (n = 1,693).
Supplementary Table S5 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Authors: Han Ji W. , Lee Soon K. , Kwon Jung H. , Nam Soon W. , Yang Hyun , Bae Si H. , Kim Ji H. , Nam Heechul , Kim Chang W. , Lee Hae L. , Kim Hee Y. , Lee Sung W. , Lee Ahlim , Chang U I. , Song Do S. , Kim Seok-Hwan , Song Myeong J. , Sung Pil S. , Choi Jong Y. , Yoon Seung K. , Jang Jeong W.
Published: July 2024

Sensitivity analyses compare the performance of the CLAM-C model in predicting 12-month death across different time periods within the study span.
Supplementary Table S1 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Authors: Han Ji W. , Lee Soon K. , Kwon Jung H. , Nam Soon W. , Yang Hyun , Bae Si H. , Kim Ji H. , Nam Heechul , Kim Chang W. , Lee Hae L. , Kim Hee Y. , Lee Sung W. , Lee Ahlim , Chang U I. , Song Do S. , Kim Seok-Hwan , Song Myeong J. , Sung Pil S. , Choi Jong Y. , Yoon Seung K. , Jang Jeong W.
Published: July 2024

Baseline characteristics of study patients from total (n = 2,626), derivation (n = 1,693), and validation (n = 933) cohorts
Supplementary Figure S9 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Authors: Han Ji W. , Lee Soon K. , Kwon Jung H. , Nam Soon W. , Yang Hyun , Bae Si H. , Kim Ji H. , Nam Heechul , Kim Chang W. , Lee Hae L. , Kim Hee Y. , Lee Sung W. , Lee Ahlim , Chang U I. , Song Do S. , Kim Seok-Hwan , Song Myeong J. , Sung Pil S. , Choi Jong Y. , Yoon Seung K. , Jang Jeong W.
Published: July 2024

Subgroup analyses.
Supplementary Figure S8 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Authors: Han Ji W. , Lee Soon K. , Kwon Jung H. , Nam Soon W. , Yang Hyun , Bae Si H. , Kim Ji H. , Nam Heechul , Kim Chang W. , Lee Hae L. , Kim Hee Y. , Lee Sung W. , Lee Ahlim , Chang U I. , Song Do S. , Kim Seok-Hwan , Song Myeong J. , Sung Pil S. , Choi Jong Y. , Yoon Seung K. , Jang Jeong W.
Published: July 2024

Kaplan–Meier curves represent the OS according to previously reported subclassifications.
Supplementary Figure S15 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Authors: Han Ji W. , Lee Soon K. , Kwon Jung H. , Nam Soon W. , Yang Hyun , Bae Si H. , Kim Ji H. , Nam Heechul , Kim Chang W. , Lee Hae L. , Kim Hee Y. , Lee Sung W. , Lee Ahlim , Chang U I. , Song Do S. , Kim Seok-Hwan , Song Myeong J. , Sung Pil S. , Choi Jong Y. , Yoon Seung K. , Jang Jeong W.
Published: July 2024

Application to each treatment subgroup in terms of progression-free survival.
Supplementary Figure S12 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Authors: Han Ji W. , Lee Soon K. , Kwon Jung H. , Nam Soon W. , Yang Hyun , Bae Si H. , Kim Ji H. , Nam Heechul , Kim Chang W. , Lee Hae L. , Kim Hee Y. , Lee Sung W. , Lee Ahlim , Chang U I. , Song Do S. , Kim Seok-Hwan , Song Myeong J. , Sung Pil S. , Choi Jong Y. , Yoon Seung K. , Jang Jeong W.
Published: July 2024

Flow chart of the analysis for first-line systemic chemotherapy.
Supplementary Figure S10 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Authors: Han Ji W. , Lee Soon K. , Kwon Jung H. , Nam Soon W. , Yang Hyun , Bae Si H. , Kim Ji H. , Nam Heechul , Kim Chang W. , Lee Hae L. , Kim Hee Y. , Lee Sung W. , Lee Ahlim , Chang U I. , Song Do S. , Kim Seok-Hwan , Song Myeong J. , Sung Pil S. , Choi Jong Y. , Yoon Seung K. , Jang Jeong W.
Published: July 2024

Application to each treatment subgroup.
Supplementary Table S6 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Authors: Yaniz-Galende Elisa , Zeng Qinghe , Bejar-Grau Juan F. , Klein Christophe , Blanc-Durand Felix , Le Formal Audrey , Pujade-Lauraine Eric , Chardin Laure , Edmond Elodie , Marty Virginie , Ray-Coquard Isabelle , Joly Florence , Ferron Gwenael , Pautier Patricia , Berton-Rigaud Dominique , Lortholary Alain , Dohollou Nadine , Desauw Christophe , Fabbro Michel , Malaurie Emmanuelle , Bonichon-Lamaichhane Nathalie , Bello Roufai Diana , Gantzer Justine , Rouleau Etienne , Genestie Catherine , Leary Alexandra
Published: July 2024

Correlation among the different immune coregulators in pre- and post-NACT tumors
Supplementary Figure S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Authors: Yaniz-Galende Elisa , Zeng Qinghe , Bejar-Grau Juan F. , Klein Christophe , Blanc-Durand Felix , Le Formal Audrey , Pujade-Lauraine Eric , Chardin Laure , Edmond Elodie , Marty Virginie , Ray-Coquard Isabelle , Joly Florence , Ferron Gwenael , Pautier Patricia , Berton-Rigaud Dominique , Lortholary Alain , Dohollou Nadine , Desauw Christophe , Fabbro Michel , Malaurie Emmanuelle , Bonichon-Lamaichhane Nathalie , Bello Roufai Diana , Gantzer Justine , Rouleau Etienne , Genestie Catherine , Leary Alexandra
Published: July 2024

Feature plots of relevant immune populations in pre- and post-NACT clusters
Supplementary Figure S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Authors: Yaniz-Galende Elisa , Zeng Qinghe , Bejar-Grau Juan F. , Klein Christophe , Blanc-Durand Felix , Le Formal Audrey , Pujade-Lauraine Eric , Chardin Laure , Edmond Elodie , Marty Virginie , Ray-Coquard Isabelle , Joly Florence , Ferron Gwenael , Pautier Patricia , Berton-Rigaud Dominique , Lortholary Alain , Dohollou Nadine , Desauw Christophe , Fabbro Michel , Malaurie Emmanuelle , Bonichon-Lamaichhane Nathalie , Bello Roufai Diana , Gantzer Justine , Rouleau Etienne , Genestie Catherine , Leary Alexandra
Published: July 2024

Change in ieCD8+ and sCD8+ populations in paired samples with NACT
Supplementary Figure S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Authors: Lian Shifeng , Lu Chenyu , Li Fugui , Yu Xia , Ai Limei , Wu Biaohua , Gong Xueyi , Zhou Wenjing , Liang Xuejun , Zhan Jiyun , Yuan Yong , Fang Fang , Liu Zhiwei , Ji Mingfang , Zheng Zongli
Published: July 2024

Supplementary Figure S1. Genome-wide copy number profile change in eight HCC patients before and after surgery. The colors green, blue, dark red, and red correspond to copy number deletion, neutral, gain, and amplification, respectively.
Supplementary Table S1 from Cell-Free Human Papillomavirus DNA Is a Sensitive Biomarker for Prognosis and for Early Detection of Relapse in Locally Advanced Cervical Cancer
Authors: Sivars Lars , Jylhä Cecilia , Crona Guterstam Ylva , Zupancic Mark , Lindqvist Britta , Nordenskjöld Magnus , Tham Emma , Hellman Kristina
Published: July 2024

Supplementary Table S1. Primers and probes used (Integrated DNA Technologies, Coralville, Iowa, USA).
Supplementary Figure S9 from Cell-Free Human Papillomavirus DNA Is a Sensitive Biomarker for Prognosis and for Early Detection of Relapse in Locally Advanced Cervical Cancer
Authors: Sivars Lars , Jylhä Cecilia , Crona Guterstam Ylva , Zupancic Mark , Lindqvist Britta , Nordenskjöld Magnus , Tham Emma , Hellman Kristina
Published: July 2024

Supplementary Figure S9. Number of copies of ctHPV DNA at different timepoints for all patients (n = 38) with only ctHPV DNA–negative samples at the end of treatment and early- and late follow-up who did not develop disease progression. Median follow-up time 37.5 months, range 18.3 – 50.0 months.
Supplementary Figure S4 from Cell-Free Human Papillomavirus DNA Is a Sensitive Biomarker for Prognosis and for Early Detection of Relapse in Locally Advanced Cervical Cancer
Authors: Sivars Lars , Jylhä Cecilia , Crona Guterstam Ylva , Zupancic Mark , Lindqvist Britta , Nordenskjöld Magnus , Tham Emma , Hellman Kristina
Published: July 2024

Supplementary Figure S4. Kaplan–Meier graphs of comparisons between patients with ctHPV DNA–positive (dotted, bottom lines) and ctHPV DNA–negative (solid, top lines) plasma at early-follow up/tumor evaluation (1-4 month after finished treatment) plasma.
Supplementary Table S3 from A Cohort Study of CNS Tumors in Multiple Endocrine Neoplasia Type 1
Authors: Graillon Thomas , Romanet Pauline , Camilla Clara , Gélin Camille , Appay Romain , Roche Catherine , Lagarde Arnaud , Mougel Grégory , Farah Kaissar , Le Bras Maëlle , Engelhardt Julien , Kalamarides Michel , Peyre Matthieu , Amelot Aymeric , Emery Evelyne , Magro Elsa , Cebula Hélène , Aboukais Rabih , Bauters Catherine , Jouanneau Emmanuel , Berhouma Moncef , Cuny Thomas , Dufour Henry , Loiseau Hugues , Figarella-Branger Dominique , Bauchet Luc , Binquet Christine , Barlier Anne , Goudet Pierre
Published: July 2024

Sporadic ependymomas characteristics
Data from Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
Authors: Lacouture Mario E. , Goleva Elena , Shah Neil , Rotemberg Veronica , Kraehenbuehl Lukas , Ketosugbo Kwami F. , Merghoub Taha , Maier Tara , Bang Alexander , Gu Stephanie , Salvador Trina , Moy Andrea P. , Lyubchenko Taras , Xiao Olivia , Hall Clifton F. , Berdyshev Evgeny , Crooks James , Weight Ryan , Kern Jeffrey A. , Leung Donald Y.M.
Published: July 2024

AbstractPurpose:
Immune-related cutaneous adverse events (ircAE) occur in ≥50% of patients treated with checkpoint inhibitors, but the underlying mechanisms for ircAEs are poorly understood.
Experimental Design:
Phenotyping/biomarker analyses were conducted in 200 patients on checkpoint inhibitors [139 with ircAEs and 61 without (control group)] to characterize their clinical presentation and immunologic endotypes. Cytokines were evaluated in skin biopsies, skin tape strip extracts, and plasma using real-time PCR and Meso Scale Discovery multiplex cytokine assays.
Results:
Eight ircAE phenotypes were identified: pruritus (26%), maculopapular rash (MPR; 21%), eczema (19%), lichenoid (11%), urticaria (8%), psoriasiform (6%), vitiligo (5%), and bullous dermatitis (4%). All phenotypes showed skin lymphocyte and eosinophil infiltrates. Skin biopsy PCR revealed the highest increase in IFNγ mRNA in patients with lichenoid (P < 0.0001) and psoriasiform dermatitis (P < 0.01) as compared with patients without ircAEs, whereas the highest IL13 mRNA levels were detected in patients with eczema (P < 0.0001, compared with control). IL17A mRNA was selectively increased in psoriasiform (P < 0.001), lichenoid (P < 0.0001), bullous dermatitis (P < 0.05), and MPR (P < 0.001) compared with control. Distinct cytokine profiles were confirmed in skin tape strip and plasma. Analysis determined increased skin/plasma IL4 cytokine in pruritus, skin IL13 in eczema, plasma IL5 and IL31 in eczema and urticaria, and mixed-cytokine pathways in MPR. Broad inhibition via corticosteroids or type 2 cytokine–targeted inhibition resulted in clinical benefit in these ircAEs. In contrast, significant skin upregulation of type 1/type 17 pathways was found in psoriasiform, lichenoid, bullous dermatitis, and type 1 activation in vitiligo.
Conclusions:
Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.
Data from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Authors: Aparicio Ana M. , Tidwell Rebecca S.S. , Yadav Shalini S. , Chen Jiun-Sheng , Zhang Miao , Liu Jingjing , Guo Shuai , Pilié Patrick G. , Yu Yao , Song Xingzhi , Vundavilli Haswanth , Jindal Sonali , Zhu Keyi , Viscuse Paul V. , Lebenthal Justin M. , Hahn Andrew W. , Soundararajan Rama , Corn Paul G. , Zurita-Saavedra Amado , Subudhi Sumit K. , Zhang Jianhua , Wang Wenyi , Huff Chad , Troncoso Patricia , Allison James P. , Sharma Padmanee , Logothetis Christopher J.
Published: July 2024

AbstractPurpose:
To determine the efficacy and safety of risk-adapted combinations of androgen signaling inhibitors and inform disease classifiers for metastatic castration–resistant prostate cancers.
Patients and Methods:
In a modular, randomized phase II trial, 192 men were treated with 8 weeks of abiraterone acetate, prednisone, and apalutamide (AAPA; module 1) and then allocated to modules 2 or 3 based on satisfactory (≥50% PSA decline from baseline and <5 circulating tumor cell/7.5 mL) versus unsatisfactory status. Men in the former were randomly assigned to continue AAPA alone (module 2A) or with ipilimumab (module 2B). Men in the latter group had carboplatin + cabazitaxel added to AAPA (module 3). Optional baseline biopsies were subjected to correlative studies.
Results:
Median overall survival (from allocation) was 46.4 [95% confidence interval (CI), 39.2–68.2], 41.4 (95% CI, 33.3–49.9), and 18.7 (95% CI, 14.3–26.3) months in modules 2A (n = 64), 2B (n = 64), and 3 (n = 59), respectively. Toxicities were within expectations. Of 192 eligible patients, 154 (80.2%) underwent pretreatment metastatic biopsies. The aggressive-variant prostate cancer molecular profile (defects in ≥2 of p53, RB1, and PTEN) was associated with unsatisfactory status. Exploratory analyses suggested that secreted phosphoprotein 1–positive and insulin-like growth factor–binding protein 2–positive macrophages, druggable myeloid cell markers, and germline pathogenic mutations were enriched in the unsatisfactory group.
Conclusions:
Adding ipilimumab to AAPA did not improve outcomes in men with androgen-responsive metastatic castration–resistant prostate cancer. Despite the addition of carboplatin + cabazitaxel, men in the unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.
Data from Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients
Authors: Nief Corrine A. , Hammer Phoebe M. , Wang Aihui , Charu Vivek , Tanweer Amina , Litkouhi Babak , Kidd Elizabeth , Gentles Andrew J. , Howitt Brooke E.
Published: July 2024

AbstractPurpose:
Risk prediction with genomic and transcriptomic data has the potential to improve patient outcomes by enabling clinicians to identify patients requiring adjuvant treatment approaches, while sparing low-risk patients from unnecessary interventions. Endometrioid endometrial carcinoma (EEC) is the most common cancer in women in developed countries, and rates of endometrial cancer are increasing.
Experimental Design:
We collected a 105-patient case-control cohort of stage I EEC comprising 45 patients who experienced recurrence less than 6 years after excision, and 60 Fédération Internationale de Gynécologie et d'Obstétrique grade-matched controls without recurrence. We first utilized two RNA-based, previously validated machine learning approaches, namely, EcoTyper and Complexity Index in Sarcoma (CINSARC). We developed Endometrioid Endometrial RNA Index (EERI), which uses RNA expression data from 46 genes to generate a personalized risk score for each patient. EERI was trained on our 105-patient cohort and tested on a publicly available cohort of 263 patients with stage I EEC.
Results:
EERI was able to predict recurrences with 94% accuracy in the training set and 81% accuracy in the test set. In the test set, patients assigned as EERI high-risk were significantly more likely to experience recurrence (30%) than the EERI low-risk group (1%) with a hazard ratio of 9.9 (95% CI, 4.1–23.8; P < 0.001).
Conclusions:
Tumors with high-risk genetic features may require additional treatment or closer monitoring and are not readily identified using traditional clinicopathologic and molecular features. EERI performs with high sensitivity and modest specificity, which may benefit from further optimization and validation in larger independent cohorts.
Data from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Authors: Lian Shifeng , Lu Chenyu , Li Fugui , Yu Xia , Ai Limei , Wu Biaohua , Gong Xueyi , Zhou Wenjing , Liang Xuejun , Zhan Jiyun , Yuan Yong , Fang Fang , Liu Zhiwei , Ji Mingfang , Zheng Zongli
Published: July 2024

AbstractPurpose:
The objective of the study was to evaluate the use of tumor content in circulating cell-free DNA (ccfDNA) for monitoring hepatocellular carcinoma (HCC) throughout its natural history.
Experimental Design:
We included 67 patients with hepatitis B virus–related HCC, of whom 17 had paired pre- and posttreatment samples, and 90 controls. Additionally, in a prospective cohort with hepatitis B virus surface antigen–positive participants recruited in 2012 and followed up biannually with blood sample collections until 2019, we included 270 repeated samples before diagnosis from 63 participants who later developed HCC (pre-HCC samples). Shallow whole-genome sequencing and the ichorCNA method were used to analyze genome-wide copy number and tumor content in ccfDNA.
Results:
High tumor content was associated with advanced tumor stage (P < 0.001) and poor survival after HCC diagnosis [HR = 12.35; 95% confidence interval (CI) = 1.413–107.9; P = 0.023]. Tumor content turned negative after surgery (P = 0.027), whereas it remained positive after transarterial chemoembolization treatment (P = 0.578). In non-HCC samples, the mean tumor content (±SD) was 0.011 (±0.007) and had a specificity of 97.8% (95% CI = 92.2%–99.7%). In pre-HCC samples, the tumor content increased from 0.014 at 4 years before diagnosis to 0.026 at 1 year before diagnosis. The sensitivity of tumor content in detecting HCC increased from 22.7% (95% CI = 11.5%–37.8%) within 1 year before diagnosis to 30.4% (95% CI = 13.2%–52.9%) at the Barcelona Clinic Liver Cancer (BCLC) stage 0/A, 81.8% (95% CI = 59.7%–94.8%) at stage B, and 95.5% (95% CI = 77.2%–99.9%) at stage C.
Conclusions:
The tumor content in ccfDNA is correlated with tumor burden and may help in monitoring HCC 1 yearearlier than clinical diagnosis and in predicting patient prognosis.
Supplementary Table 2 from CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool
Authors: Kaptein Paulien , Slingerland Nadine , Metoikidou Christina , Prinz Felix , Brokamp Simone , Machuca-Ostos Mercedes , de Roo Guido , Schumacher Ton N.M. , Yeung Yik A. , Moynihan Kelly D. , Djuretic Ivana M. , Thommen Daniela S.
Published: July 2024

Human flow cytometry antibodies.
Supplementary Figure 7 from CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool
Authors: Kaptein Paulien , Slingerland Nadine , Metoikidou Christina , Prinz Felix , Brokamp Simone , Machuca-Ostos Mercedes , de Roo Guido , Schumacher Ton N.M. , Yeung Yik A. , Moynihan Kelly D. , Djuretic Ivana M. , Thommen Daniela S.
Published: July 2024

Response dynamics of intratumoral CD8+ T cell states to CD8-IL2 and other IL2 conditions.
Supplementary Figure 5 from CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool
Authors: Kaptein Paulien , Slingerland Nadine , Metoikidou Christina , Prinz Felix , Brokamp Simone , Machuca-Ostos Mercedes , de Roo Guido , Schumacher Ton N.M. , Yeung Yik A. , Moynihan Kelly D. , Djuretic Ivana M. , Thommen Daniela S.
Published: July 2024

Single-cell RNA-sequencing (scRNAseq) design and analysis.
Supplementary Figure 3 from CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool
Authors: Kaptein Paulien , Slingerland Nadine , Metoikidou Christina , Prinz Felix , Brokamp Simone , Machuca-Ostos Mercedes , de Roo Guido , Schumacher Ton N.M. , Yeung Yik A. , Moynihan Kelly D. , Djuretic Ivana M. , Thommen Daniela S.
Published: July 2024

Comparison of CD8-IL2 induced T cell activation to anti-CD8, IL15 and PD1- IL2 treatment.
Supplementary Figure 11 from CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool
Authors: Kaptein Paulien , Slingerland Nadine , Metoikidou Christina , Prinz Felix , Brokamp Simone , Machuca-Ostos Mercedes , de Roo Guido , Schumacher Ton N.M. , Yeung Yik A. , Moynihan Kelly D. , Djuretic Ivana M. , Thommen Daniela S.
Published: July 2024

Comparison of intratumoral T cells responding to CD8-IL2 and to anti-PD 1.
Supplementary Table S3 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Authors: Moynihan Kelly D. , Kumar Manu P. , Sultan Hussein , Pappas Danielle C. , Park Terrence , Chin S. Michael , Bessette Paul , Lan Ruth Y. , Nguyen Henry C. , Mathewson Nathan D. , Ni Irene , Chen Wei , Lee Yonghee , Liao-Chan Sindy , Chen Jessie , Schumacher Ton N.M. , Schreiber Robert D. , Yeung Yik A. , Djuretic Ivana M.
Published: July 2024

Supplementary Table S3, Single-cell RNA sequencing reagents used in this study
Supplementary Figure S8 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Authors: Moynihan Kelly D. , Kumar Manu P. , Sultan Hussein , Pappas Danielle C. , Park Terrence , Chin S. Michael , Bessette Paul , Lan Ruth Y. , Nguyen Henry C. , Mathewson Nathan D. , Ni Irene , Chen Wei , Lee Yonghee , Liao-Chan Sindy , Chen Jessie , Schumacher Ton N.M. , Schreiber Robert D. , Yeung Yik A. , Djuretic Ivana M.
Published: July 2024

Supplementary Figure S8: Differential expression by treatment.
Supplementary Figure S6 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Authors: Moynihan Kelly D. , Kumar Manu P. , Sultan Hussein , Pappas Danielle C. , Park Terrence , Chin S. Michael , Bessette Paul , Lan Ruth Y. , Nguyen Henry C. , Mathewson Nathan D. , Ni Irene , Chen Wei , Lee Yonghee , Liao-Chan Sindy , Chen Jessie , Schumacher Ton N.M. , Schreiber Robert D. , Yeung Yik A. , Djuretic Ivana M.
Published: July 2024

Supplementary Figure S6: Characterization of antigen-specific CD8+ T cells in MC38 tumors.
Supplementary Figure S4 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Authors: Moynihan Kelly D. , Kumar Manu P. , Sultan Hussein , Pappas Danielle C. , Park Terrence , Chin S. Michael , Bessette Paul , Lan Ruth Y. , Nguyen Henry C. , Mathewson Nathan D. , Ni Irene , Chen Wei , Lee Yonghee , Liao-Chan Sindy , Chen Jessie , Schumacher Ton N.M. , Schreiber Robert D. , Yeung Yik A. , Djuretic Ivana M.
Published: July 2024

Supplementary Figure S4: Further characterization of CD8-mIL2 activity in mouse tumor models.
Supplementary Figure S1 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Authors: Moynihan Kelly D. , Kumar Manu P. , Sultan Hussein , Pappas Danielle C. , Park Terrence , Chin S. Michael , Bessette Paul , Lan Ruth Y. , Nguyen Henry C. , Mathewson Nathan D. , Ni Irene , Chen Wei , Lee Yonghee , Liao-Chan Sindy , Chen Jessie , Schumacher Ton N.M. , Schreiber Robert D. , Yeung Yik A. , Djuretic Ivana M.
Published: July 2024

Supplementary Figure S1: CD8+ T cells drive anti-tumor activity but NK cells are responsible for toxicity with not-α-IL2 therapy.
Table S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Authors: Dias Matheus Henrique , Friskes Anoek , Wang Siying , Fernandes Neto Joao M. , van Gemert Frank , Mourragui Soufiane , Papagianni Chrysa , Kuiken Hendrik J. , Mainardi Sara , Alvarez-Villanueva Daniel , Lieftink Cor , Morris Ben , Dekker Anna , van Dijk Emma , Wilms Lieke H.S. , da Silva Marcelo S. , Jansen Robin A. , Mulero-Sánchez Antonio , Malzer Elke , Vidal August , Santos Cristina , Salazar Ramón , Wailemann Rosangela A.M. , Torres Thompson E.P. , De Conti Giulia , Raaijmakers Jonne A. , Snaebjornsson Petur , Yuan Shengxian , Qin Wenxin , Kovach John S. , Armelin Hugo A. , te Riele Hein , van Oudenaarden Alexander , Jin Haojie , Beijersbergen Roderick L. , Villanueva Alberto , Medema Rene H. , Bernards Rene
Published: July 2024

Supplementary table 6: Stress-focused drug screens AUC differences in SW-480 cells Area Under the Curve (AUC) from each compound of the stress-focused drug screen in the presence or absence of LB-100. Compounds are ranked by the difference in the AUC between LB-100-treated and untreated samples.
Table S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Authors: Dias Matheus Henrique , Friskes Anoek , Wang Siying , Fernandes Neto Joao M. , van Gemert Frank , Mourragui Soufiane , Papagianni Chrysa , Kuiken Hendrik J. , Mainardi Sara , Alvarez-Villanueva Daniel , Lieftink Cor , Morris Ben , Dekker Anna , van Dijk Emma , Wilms Lieke H.S. , da Silva Marcelo S. , Jansen Robin A. , Mulero-Sánchez Antonio , Malzer Elke , Vidal August , Santos Cristina , Salazar Ramón , Wailemann Rosangela A.M. , Torres Thompson E.P. , De Conti Giulia , Raaijmakers Jonne A. , Snaebjornsson Petur , Yuan Shengxian , Qin Wenxin , Kovach John S. , Armelin Hugo A. , te Riele Hein , van Oudenaarden Alexander , Jin Haojie , Beijersbergen Roderick L. , Villanueva Alberto , Medema Rene H. , Bernards Rene
Published: July 2024

Supplementary table 1: Cancer cell lines with oncogenic drivers The mutational status of the cell lines was compiled from the ATCC, Catalogue of Somatic Mutations in Cancer (COSMIC) and Cell Model Passport, Wellcome Trust Sanger Institute, and Depmap portal databases.
Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Authors: Dias Matheus Henrique , Friskes Anoek , Wang Siying , Fernandes Neto Joao M. , van Gemert Frank , Mourragui Soufiane , Papagianni Chrysa , Kuiken Hendrik J. , Mainardi Sara , Alvarez-Villanueva Daniel , Lieftink Cor , Morris Ben , Dekker Anna , van Dijk Emma , Wilms Lieke H.S. , da Silva Marcelo S. , Jansen Robin A. , Mulero-Sánchez Antonio , Malzer Elke , Vidal August , Santos Cristina , Salazar Ramón , Wailemann Rosangela A.M. , Torres Thompson E.P. , De Conti Giulia , Raaijmakers Jonne A. , Snaebjornsson Petur , Yuan Shengxian , Qin Wenxin , Kovach John S. , Armelin Hugo A. , te Riele Hein , van Oudenaarden Alexander , Jin Haojie , Beijersbergen Roderick L. , Villanueva Alberto , Medema Rene H. , Bernards Rene
Published: July 2024

Figure S7: Normal tissues from the orthotopic CRC PDXs are not affected by LB-100, adavosertib, or the combination. Representative Hematoxylin & Eosin (H&E) stainings of the heart, liver, lung, and spleen from the PDOX1 PDXs treated as indicated. Original magnifications are indicated.